ZBH Medical Devices · Orthopedics · Medical devices · Robotics · Thesis updated June 13, 2026

A sales reset tests Zimmer Biomet

Q1 2026 net sales rose 9.3%, but the beat had help from Paragon 28, currency, and late-quarter customer buys.
The main story is a multi-year U.S. sales force conversion from independent agents to employees.
U.S. Knees grew only 2.2% in Q1, which may be the first visible sign of disruption.
S.E.T. and Technology are helping offset the pressure, with Q1 growth of 19.5% and 14.6%.
Finn sees a balanced case: fair financial health and valuation, but mixed growth and sentiment.

01 Running thesis

The transition year

Zimmer Biomet had a strong Q1 on the surface. Net sales rose 9.3% versus last year. But management said the growth came from several helpers: the Paragon 28 acquisition, favorable currency moves, opportunistic end-of-quarter customer purchases, ROSA Robot and bone cement timing, market growth, and new products.

That means the key question is not whether Q1 looked good. The key question is how much of that growth is repeatable. Management kept full-year organic constant currency revenue growth guidance at 1% to 3%, even after the Q1 beat. That points to a slower core business than the headline number suggests.

The bull case is that Zimmer Biomet is managing a hard sales change with only modest damage. Management said the U.S. move to a dedicated and specialized sales channel is on plan, and that transitioned territories are seeing rapid productivity gains. S.E.T., robotics, bone cement, and surgical products give the company extra growth sources while the large joint business resets.

The bear case is that the strong Q1 number is hiding deeper trouble. U.S. Knees grew only 2.2%, much weaker than the global Knees growth rate of 4.5%. If sales people leave, surgeon relationships break, or customer buying was pulled forward from Q2, growth could slow more as the conversion continues through 2026.

May 2026→Q1 2026 net sales rose 9.3%, but the 10-Q tied the beat to Paragon 28, currency, end-of-quarter customer purchases, and timing. The thesis stays centered on sales force execution because U.S. Knees grew only 2.2%.

Apr 2026→Management said the U.S. sales channel change was progressing as planned, with modest disruption and productivity gains in transitioned territories. The company maintained 1% to 3% organic revenue growth guidance while raising adjusted EPS guidance to $8.40 to $8.55.

Feb 2026▼The 2025 Form 10-K gave formal risk language for the sales force conversion. It warned of operational disruption, higher costs, reduced sales, and possible loss of sales personnel.

Feb 2026▼The Q4 2025 call made the U.S. sales force transformation the main investment issue. Management guided to only 1% to 3% organic constant currency revenue growth for 2026 and shifted near-term capital allocation toward shareholder returns over M&A.

Nov 2025▲The Q3 2025 10-Q confirmed the Monogram acquisition had closed. Segment growth was broad, with S.E.T. helped by Paragon 28 and Technology sales rebounding.

Aug 2025▲The Q2 2025 earnings call added the Monogram robotics deal to the thesis. Management said the deal should add revenue growth beginning in 2027 and become accretive after that.

Aug 2025▲The Q2 2025 10-Q strengthened the Paragon 28 case, with that deal contributing strongly to S.E.T. growth. The expected 2025 tariff headwind also fell to about $40 million.

May 2025▼The Q1 2025 call lowered adjusted EPS guidance because of an unexpected $60 million to $80 million tariff hit. Management also disclosed an SEC investigation tied to Paragon 28 pre-acquisition financials.

02 Business model

Implants, instruments, and surgeon relationships

Zimmer Biomet makes money by designing, making, and selling products used in musculoskeletal care. In plain English, that means hips, knees, trauma products, sports medicine tools, bone cement, surgical products, and digital systems that help surgeons plan and place implants.

The business benefits from aging patients and active older adults who need joint and bone care. These procedures also depend on surgeon trust. That makes the sales channel very important, because reps help hospitals and surgeons get the right products, tools, and support in the operating room.

The company is now changing that sales channel in the U.S. It has started a multi-year plan to convert substantial portions of its U.S. sales force from independent agents into Zimmer Biomet employees. The goal is more dedicated coverage and more product specialization, but the near-term cost is disruption risk.

Capital allocation has also shifted. Management has paused new M&A in 2026 to focus on integrating recent deals and fixing the sales model. In the near term, the company plans to prioritize return of capital to shareholders over M&A, including the $1.5B share repurchase program announced in February 2026.

03 Product portfolio

Where the product bets sit

Cash cow

Knees

Knees are the largest product category by Q1 2026 sales. Global sales grew 4.5%, but U.S. growth was only 2.2%, so this is the main place to watch for sales disruption.

Cash cow

Hips

Hips are another core joint franchise. Q1 2026 global sales grew 5.7%, with U.S. growth of 5.0%, which looks steadier than Knees for now.

Growth engine

S.E.T.

S.E.T. means Sports Medicine, Extremities, and Trauma. It grew 19.5% in Q1 2026, helped heavily by Paragon 28, which added 16.0 percentage points to the segment's growth.

Growth engine

ROSA robotics and Technology

ROSA is Zimmer Biomet's main robot platform. The Technology & Data, Bone Cement and Surgical category grew 14.6% in Q1 2026, helped by ROSA Robot and bone cement timing.

Option

TMINI partnership

The THINK Surgical TMINI handheld system gives Zimmer Biomet another robotics format. It helps the company serve surgeons who may not want a larger robot setup.

Option

Monogram mBôs

Monogram adds a semi and fully autonomous, AI-driven robotics platform. The upside is meaningful, but commercialization depends on regulation, surgeon adoption, and integration.

04 Business segments

Q1 sales mix

Knees40%modest

Hips25%modest

S.E.T.27%growing fast

Technology & Data, Bone Cement and Surgical8%growing fast

Shares are based on Q1 2026 net sales by product category from the Form 10-Q. Knees and Hips remain the core, but S.E.T. is now large enough to matter, partly because of Paragon 28.

05 Risk factors

What could go wrong

Sales force conversion disruption

High impact · High odds

Zimmer Biomet is converting much of its U.S. sales force from independent agents to employees. The 2025 Form 10-K says this can create operational, legal, financial, and cultural challenges. The specific danger is lost sales people, weaker surgeon relationships, coverage gaps, and lower net sales.

We watchTrack the percent of U.S. sales force converted, U.S. Knees growth, U.S. Hips growth, and any comments on sales personnel loss.

Weak organic demand masked by Q1 timing

High impact · Medium odds

Q1 net sales rose 9.3%, but management named several temporary or non-core helpers. These included Paragon 28, currency, opportunistic end-of-quarter customer purchases, and timing of ROSA Robot and bone cement sales. If those buys pulled demand from Q2, the underlying growth rate could look weaker later in 2026.

We watchCompare reported growth with organic constant currency guidance of 1% to 3%, and listen for any Q2 payback from late-quarter purchases.

Monogram robotics commercialization

Medium impact · Medium odds

The Monogram mBôs platform could make Zimmer Biomet stronger in autonomous orthopedic robotics. But the product must clear demanding regulatory steps and prove it can win surgeon trust. Delays could push out the expected 2027 revenue contribution.

We watchWatch for regulatory updates, launch timing, surgeon adoption comments, and whether management still expects 2027 revenue contribution and EPS neutrality.

CFO succession during a heavy reset

Medium impact · Medium odds

CFO Suky Upadhyay is departing while Zimmer Biomet is handling a sales force change, Paragon 28 integration, and Monogram integration. A slow search or rough handoff could distract management. It could also raise questions about capital allocation.

We watchLook for the timing and background of the new CFO, plus any change to the $1.5B buyback plan.

Pricing pressure in medical devices

Medium impact · High odds

The Q1 2026 filing said global selling prices had a negative 0.4% effect on year-over-year sales. Hospitals, health systems, and government buyers keep pushing prices lower in many markets. Zimmer Biomet must offset that with volume, mix, new products, and cost control.

We watchTrack quarterly price impact, gross margin, and whether new products can offset hospital price pressure.

06 Quick answers

In one breath

What does Zimmer Biomet do?

Zimmer Biomet sells orthopedic implants and related surgical products. Its main categories are Knees, Hips, S.E.T., and Technology & Data, Bone Cement and Surgical.

Why is the U.S. sales force change so important?

The company is moving many U.S. sales people from independent agent status to employee status. That could improve focus and productivity over time, but it can also disrupt surgeon relationships and sales coverage during the change.

Was Q1 2026 growth as strong as it looked?

The headline was strong, with net sales up 9.3%. The quality of that growth is less clear because it included Paragon 28, currency benefits, opportunistic end-of-quarter customer purchases, and timing of ROSA Robot and bone cement sales.

What should investors watch next?

The main signals are organic growth versus the 1% to 3% guide, U.S. Knees and Hips growth, sales force conversion progress, and CFO succession. Any detail on Q1 customer purchases pulling demand from Q2 also matters.